A Phase II Study of Cyclophosphamide, Topotecan, and Bevacizumab in Patients with Relapsed or Refractory Ewing's Sarcoma and Neuroblastoma

Full Title

A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients with Relapsed/Refractory Ewing’s Sarcoma and Neuroblastoma Back to top

Purpose

Cyclophosphamide and topotecan are standard anticancer drugs used to treat patients with Ewing’s sarcoma and neuroblastoma. Despite this therapy, however, in some patients the cancer returns or persists. In this study, researchers are evaluating the safety and effectiveness of adding the drug bevacizumab to cyclophosphamide and topotecan therapy in children and adolescents with Ewing’s sarcoma or neuroblastoma that has returned or persists despite standard therapy.

Bevacizumab works by inhibiting the formation of blood vessels that tumors need to grow and spread. It is given intravenously (by vein). It is already approved for the treatment of several other types of cancer, but its use in this study is considered investigational.

This study is coordinated by POETIC, a consortium of several U.S. hospitals that conducts clinical trials for children with cancer.

Back to top

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of Ewing’s sarcoma or neuroblastoma that has returned or persists despite at least one prior regimen of therapy.
  • Patients must be age 21 or younger.
  • Patients may have had prior cyclophosphamide or topotecan, but not bevacizumab.
  • Patients must have recovered from the acute side effects of prior therapy before entering the study.

For more information about this study and to inquire about eligibility, please contact Dr. Tanya Trippett at 212-639-8267.

Back to top

Protocol

11-183

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators

Locations